Comparison of various pharmaceutical properties of clobetasol propionate cream formulations - considering stability of mixture with moisturizer.

Clobetasol propionate Cream Generic Mixture Near infrared spectroscopy Rheological property TG-DTA

Journal

Journal of pharmaceutical health care and sciences
ISSN: 2055-0294
Titre abrégé: J Pharm Health Care Sci
Pays: England
ID NLM: 101672177

Informations de publication

Date de publication:
2020
Historique:
received: 21 10 2019
accepted: 20 01 2020
entrez: 5 2 2020
pubmed: 6 2 2020
medline: 6 2 2020
Statut: epublish

Résumé

The clobetasol propionate cream formulations (CLB Pharmaceutical properties of CLB The hardness of Dermovate® (DRM), Glydil® (GDL), and Myalone® (MYA) was greater than that of CLB Thus, even for cream formulations with the same active pharmaceutical ingredient, pharmaceutical properties and stability of mixture with moisturizer may different significantly.

Sections du résumé

BACKGROUND BACKGROUND
The clobetasol propionate cream formulations (CLB
METHOD METHODS
Pharmaceutical properties of CLB
RESULTS RESULTS
The hardness of Dermovate® (DRM), Glydil® (GDL), and Myalone® (MYA) was greater than that of CLB
CONCLUSION CONCLUSIONS
Thus, even for cream formulations with the same active pharmaceutical ingredient, pharmaceutical properties and stability of mixture with moisturizer may different significantly.

Identifiants

pubmed: 32015896
doi: 10.1186/s40780-020-0158-y
pii: 158
pmc: PMC6990562
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1

Informations de copyright

© The Author(s). 2020.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interest.

Références

Chem Pharm Bull (Tokyo). 2015;63(1):43-8
pubmed: 25400272
Int J Pharm. 2014 Mar 10;463(1):62-7
pubmed: 24406671
Talanta. 2013 Nov 15;116:65-70
pubmed: 24148374
Chem Pharm Bull (Tokyo). 2015;63(5):377-83
pubmed: 25948331
J Am Acad Dermatol. 1993 Aug;29(2 Pt 1):197-202
pubmed: 8335738
Eur J Pharm Sci. 2018 Nov 1;124:199-207
pubmed: 30171983
Chem Pharm Bull (Tokyo). 2016 Jul 1;64(7):1047-55
pubmed: 27109377
Chem Pharm Bull (Tokyo). 2012;60(2):260-6
pubmed: 22293488
J Biosci Bioeng. 2008 Dec;106(6):537-40
pubmed: 19134547
Int J Pharm. 2012 Apr 15;426(1-2):54-60
pubmed: 22286017
Spectrochim Acta A Mol Biomol Spectrosc. 2010 May;75(5):1535-9
pubmed: 20299275
J Dent Res. 1992 Mar;71(3):438-42
pubmed: 1573074
Drug Dev Ind Pharm. 2010 Jun;36(6):625-31
pubmed: 19954404
Chem Pharm Bull (Tokyo). 2012;60(5):624-31
pubmed: 22689400
J Pharm Biomed Anal. 2017 Aug 5;142:178-189
pubmed: 28514717
Results Pharma Sci. 2013 Nov 06;3:15-9
pubmed: 25756000
Skin Pharmacol Physiol. 2009;22(3):142-50
pubmed: 19246962
J Sci Food Agric. 2014 Mar 30;94(5):1026-33
pubmed: 23983143
Chem Pharm Bull (Tokyo). 2015;63(9):663-8
pubmed: 26329859
Pharmazie. 2014 Feb;69(2):104-8
pubmed: 24640598
Int J Pharm. 2005 Dec 8;306(1-2):56-70
pubmed: 16266793
Int J Pharm. 2013 May 1;448(1):305-12
pubmed: 23541986

Auteurs

Yoshihisa Yamamoto (Y)

1Faculty of Pharmaceutical Sciences, Teikyo Heisei University, 4-21-2, Nakano, Nakano-ku, Tokyo, 164-8530 Japan.

Yoshinori Onuki (Y)

2Faculty of Pharmacy and Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama, 930-0194 Japan.

Toshiro Fukami (T)

3Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo 204-8588 Japan.

Tatsuo Koide (T)

4Division of Drugs, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki-ku, Kawasaki, Kanagawa 210-9501 Japan.

Classifications MeSH